TY - JOUR
T1 - Neurocognitive dysfunction in subjects at clinical high risk for psychosis
T2 - A meta-analysis
AU - Zheng, Wei
AU - Zhang, Qing E.
AU - Cai, Dong Bin
AU - Ng, Chee H.
AU - Ungvari, Gabor S.
AU - Ning, Yu Ping
AU - Xiang, Yu Tao
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Findings of neurocognitive dysfunction in subjects at Clinical High Risk for Psychosis (CHR-P) have been controversial. This meta-analysis systematically examined studies of neurocognitive functions using the MATRICS Consensus Cognitive Battery (MCCB) in CHR-P. An independent literature search of both English and Chinese databases was conducted by two reviewers. Standardized mean difference (SMD) was calculated using a random effects model to evaluate the effect size of the meta-analytic results. Six case-control studies (n = 396) comparing neurocognitive functions between CHR-P subjects (n = 197) and healthy controls (n = 199) using the MCCB were identified; 4 (66.7%) studies were rated as “high quality”. Compared to healthy controls, CHR-P subjects showed impairment with large effect size in overall cognition (n = 128, SMD = −1.00, 95%CI: −1.38, −0.63, P < 0.00001; I2 = 2%), processing speed (SMD = −1.21) and attention/vigilance (SMD = −0.83), and with medium effect size in working memory (SMD = −0.76), reasoning and problem solving (SMD = −0.71), visual (SMD = −0.68) and verbal learning (SMD = −0.67). No significant difference between CHR-P subjects and controls was found regarding social cognition (SMD = −0.33, 95%CI: −0.76, 0.10, P = 0.14; I2 = 70%) with small effect size. Apart from social cognition, CHR-P subjects performed worse than healthy control in all MCCB cognitive domains, particularly in processing speed, attention/vigilance and working memory.
AB - Findings of neurocognitive dysfunction in subjects at Clinical High Risk for Psychosis (CHR-P) have been controversial. This meta-analysis systematically examined studies of neurocognitive functions using the MATRICS Consensus Cognitive Battery (MCCB) in CHR-P. An independent literature search of both English and Chinese databases was conducted by two reviewers. Standardized mean difference (SMD) was calculated using a random effects model to evaluate the effect size of the meta-analytic results. Six case-control studies (n = 396) comparing neurocognitive functions between CHR-P subjects (n = 197) and healthy controls (n = 199) using the MCCB were identified; 4 (66.7%) studies were rated as “high quality”. Compared to healthy controls, CHR-P subjects showed impairment with large effect size in overall cognition (n = 128, SMD = −1.00, 95%CI: −1.38, −0.63, P < 0.00001; I2 = 2%), processing speed (SMD = −1.21) and attention/vigilance (SMD = −0.83), and with medium effect size in working memory (SMD = −0.76), reasoning and problem solving (SMD = −0.71), visual (SMD = −0.68) and verbal learning (SMD = −0.67). No significant difference between CHR-P subjects and controls was found regarding social cognition (SMD = −0.33, 95%CI: −0.76, 0.10, P = 0.14; I2 = 70%) with small effect size. Apart from social cognition, CHR-P subjects performed worse than healthy control in all MCCB cognitive domains, particularly in processing speed, attention/vigilance and working memory.
KW - Clinical high risk for psychosis
KW - MCCB
KW - Meta-analysis
KW - Neurocognitive function
KW - Psychosis
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85047083619&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2018.05.001
DO - 10.1016/j.jpsychires.2018.05.001
M3 - Article
C2 - 29772485
AN - SCOPUS:85047083619
VL - 103
SP - 38
EP - 45
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
SN - 0022-3956
ER -